Aemetis (NASDAQ:AMTX) Raised to “Sell” at StockNews.com

StockNews.com upgraded shares of Aemetis (NASDAQ:AMTX) to a sell rating in a research note published on Wednesday morning.

A number of other equities analysts have also recently issued reports on AMTX. Ascendiant Capital Markets cut their price target on Aemetis from $20.00 to $19.00 and set a “buy” rating on the stock in a report on Tuesday, September 3rd. HC Wainwright reissued a “buy” rating and set a $28.00 target price on shares of Aemetis in a research note on Monday. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $12.95.

Aemetis Stock Up 1.5 %

AMTX stock opened at $2.63 on Wednesday. The firm has a market cap of $130.80 million, a price-to-earnings ratio of -1.16 and a beta of 1.35. The company’s fifty day simple moving average is $3.29 and its 200 day simple moving average is $2.99. Aemetis has a 12-month low of $2.10 and a 12-month high of $7.03.

Aemetis (NASDAQ:AMTX) last announced its quarterly earnings data on Tuesday, November 12th. The specialty chemicals company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.09. The business had revenue of $81.44 million during the quarter, compared to analyst estimates of $77.79 million. During the same period in the prior year, the firm earned ($0.59) earnings per share. Research analysts expect that Aemetis will post -2.02 earnings per share for the current year.

Institutional Trading of Aemetis

Several hedge funds have recently bought and sold shares of AMTX. FMR LLC lifted its position in Aemetis by 68.2% in the 3rd quarter. FMR LLC now owns 22,531 shares of the specialty chemicals company’s stock valued at $52,000 after acquiring an additional 9,137 shares in the last quarter. Hutchinson Capital Management CA bought a new position in shares of Aemetis in the second quarter valued at approximately $70,000. Barclays PLC boosted its position in shares of Aemetis by 274.6% during the third quarter. Barclays PLC now owns 47,496 shares of the specialty chemicals company’s stock valued at $109,000 after buying an additional 34,816 shares during the last quarter. Rhumbline Advisers raised its position in Aemetis by 2,837.1% in the 2nd quarter. Rhumbline Advisers now owns 52,309 shares of the specialty chemicals company’s stock valued at $157,000 after buying an additional 50,528 shares during the last quarter. Finally, Wellington Management Group LLP purchased a new position in Aemetis during the 3rd quarter worth $177,000. Institutional investors and hedge funds own 27.02% of the company’s stock.

Aemetis Company Profile

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.